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Abstract
Background: The development of an autistic brain is a highly complex process as evident from the involvement of
various genetic and non-genetic factors in the etiology of the autism spectrum disorder (ASD). Despite being a
multifactorial neurodevelopmental disorder, autistic patients display a few key characteristics, such as the impaired
social interactions and elevated repetitive behaviors, suggesting the perturbation of specific neuronal circuits resulted
from abnormal signaling pathways during brain development in ASD. A comprehensive review for autistic signaling
mechanisms and interactions may provide a better understanding of ASD etiology and treatment.
Main body: Recent studies on genetic models and ASD patients with several different mutated genes revealed the
dysregulation of several key signaling pathways, such as WNT, BMP, SHH, and retinoic acid (RA) signaling. Although no
direct evidence of dysfunctional FGF or TGF-β signaling in ASD has been reported so far, a few examples of indirect
evidence can be found. This review article summarizes how various genetic and non-genetic factors which have
been reported contributing to ASD interact with WNT, BMP/TGF-β, SHH, FGF, and RA signaling pathways. The
autism-associated gene ubiquitin-protein ligase E3A (UBE3A) has been reported to influence WNT, BMP, and RA
signaling pathways, suggesting crosstalk between various signaling pathways during autistic brain development.
Finally, the article comments on what further studies could be performed to gain deeper insights into the
understanding of perturbed signaling pathways in the etiology of ASD.
Conclusion: The understanding of mechanisms behind various signaling pathways in the etiology of ASD may
help to facilitate the identification of potential therapeutic targets and design of new treatment methods.
Keywords: WNT, BMP/TGF-β, SHH, FGF, Retinoic acid (RA), Signaling crosstalk, Autism spectrum disorder,
Neurodevelopmental disorders
Background
Autism spectrum disorder (ASD) is a multifactorial neu-
rodevelopmental disorder characterized by impaired social
interactions and elevated repetitive behaviors, in which
various circuits in the sensory, prefrontal, hippocampal,
cerebellar, striatal, and other midbrain regions are per-
turbed [1, 2]. Compared to de novo non-coding variations,
the de novo coding variants have a strong association with
ASD as shown by the whole-genome sequence association
(WGSA) studies in 519 ASD families [3]. Kosmicki et al.
further showed CHD8, ARID1B, DYRK1A, SYNGAP1,
ADNP, ANK2, DSCAM, SCN2A, ASH1L, CHD2, KDM5B,
and POGZ genes with ≥ 3 class 1 de novo
protein-truncating variants (PTVs) in individuals with
ASD [4]. ANK2, CHD8, CUL3, DYRK1A, GRIN2B, KAT-
NAL2, POGZ, SCN2A, and TBR1 genes are identified as
high-confidence ASD risk genes, of which CHD8 is
strongly associated with ASD because of the largest num-
ber of de novo loss-of-function (LOF) mutations observed
in patients [5, 6]. Various gene mutations reported in ASD
patients are either core components of the WNT signaling
pathway or their modulators [7–9]. More recently, a few
reports support the idea of modulation of bone morpho-
genetic protein (BMP) signaling as a contributing factor in
ASD model organisms and humans. For instance,
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Neuroligins (NLGN), fragile X mental retardation 1
(FMR1), ubiquitin-protein ligase E3A (UBE3A), and DLX,
which modulate BMP signaling, have been found to be
associated with ASD [10–13]. Dysregulation of sonic
hedgehog (SHH) [14, 15], fibroblast growth factor (FGF)
[16], transforming growth factor β (TGF-β) [17, 18], and
retinoic acid (RA) [19] signaling pathways have also been
implicated in the pathogenesis of ASD. Valproic acid
(VPA), used in the treatment of epilepsy and bipolar dis-
order, may affect the WNT/β-catenin signaling pathway.
However, its prenatal exposure in rats also causes suscep-
tibility to autism [20]. Due to the scarcity of information
on the mechanisms underlying the etiologies of ASD, the
success of therapeutic strategies is greatly limited.
Altered WNT signaling in ASD
WNT signaling is fundamental for neurodevelopmental
and post-neurodevelopmental processes, such as CNS
regionalization, neural progenitor differentiation, neuronal
migration, axon guidance, dendrite development, synapto-
genesis, adult neurogenesis, and neural plasticity [21–30],
and therefore, any perturbation in WNT signaling may
trigger the advent of disorders related to the structures
and functions of the CNS [9, 31]. Studies in genetically
modified animal models and human induced pluripo-
tent stem cell (hiPSC) models, along with large-scale
human genomic studies in several neurodevelopmental
disorders over the last few decades, have revealed the
importance of spatiotemporal regulation of WNT
signaling throughout the lifespan of an animal [9].
Moreover, dysregulation of WNT signaling has been
reported in several psychiatric disorders, including
ASD, bipolar disorder, and schizophrenia, as well as in
case of intellectual disability [8, 9, 31–34]. Although
several genetic and epigenetic factors have been linked
with the etiologies of neurodevelopmental disorders,
they often seem to affect a few common processes, such
as chromatin remodeling, WNT signaling, and synaptic
function [32, 35, 36]. Despite the heterogeneity in
WNT signaling, it is broadly classified into “canonical”
(β-catenin-dependent) and “non-canonical” (β-cateni-
n-independent) pathways [37, 38]. Both canonical and
non-canonical WNT signaling pathways play crucial
roles in neural development and related neurodevelop-
mental disorders.
Genetic etiologies
Several genetic loci/mutations linked to and/or reported
in ASD patients are either core components of canonical
WNT signaling, such as β-catenin (CTNNB1) [8, 9, 36, 39]
and adenomatous polyposis coli (APC) [1], or
non-canonical WNT signaling, such as PRICKLE2 [40],
suggesting crucial roles of both canonical and
non-canonical WNT signaling pathways in the etiolo-
gies of ASD (Table 1 and Fig. 1).
Core components of canonical WNT signaling
WNTs Among 19 WNT ligands, mutations in WNT1,
WNT2, WNT3, and WNT9B have been linked with
ASD. A rare WNT1 missense variant found in ASD pa-
tients has a higher capability than the wild-type WNT1
to activate WNT/β-catenin signaling [34]. Rare variants
in WNT2, WNT3, and WNT9B have also been found in
ASD patients [41–44]. Notably, WNT3 expression is ele-
vated in the prefrontal cortex of ASD patients [45], sug-
gesting overactivation of WNT signaling leads to ASD
pathogenesis. In animal models, Wnt1 is required for
midbrain and cerebellar development [46–48]. Wnt2 has
been shown to be sufficient for cortical dendrite growth
and dendritic spine formation, and its expression is reg-
ulated by a brain-derived neurotrophic factor (BDNF)
[49], while altered dendritic spines result in neurodeve-
lopmental and neurodegenerative disorders [49]. Wnt3 is
essential for gastrulation and regulates hippocampal
neurogenesis [50, 51]. Loss-of-function of T-brain-1
(Tbr1), a T-box transcription factor and one of the
high-confidence ASD risk genes, in cortical layer 6 neu-
rons (Tbr1layer6 mutant) during late mouse gestation has
been reported to cause a decrease in inhibitory synaptic
density and excitatory synapse numbers [52]. It is im-
portant to note that the restoration of Wnt7b expression
rescues the synaptic deficit in Tbr1layer6 mutant neurons
[52]. Wnt9b promotes lip/palate formation and fusion
[53, 54], while its role in neurodevelopment remains un-
clear. In addition to the other WNT ligands, there are
various types of WNT receptors, including FZD1 to
FZD10, LRP5/6, RYK, and ROR1/2 [30, 55], whose roles
in ASD etiology remain elusive.
APC The tumor suppressor APC is a key component of
the β-catenin-destruction complex [56]. Human APC
inactivating gene mutations have been linked to ASD
[57, 58]. Compared with wild-type littermates, condi-
tional knockout (cKO) Apc mice exhibit learning and
memory impairment and autistic-like behaviors [1].
β-catenin and canonical WNT target gene expressions
(Dkk1, Sp5, Neurog1, Syn2) are increased in Apc-cKO
forebrain neurons [1]. Moreover, the lysates from the
hippocampal, cortical, and striatal regions of Apc-cKO
mice showed higher β-catenin levels compared to
those of control mice [1]. These results also indicate
that overactivation of WNT/β-catenin signaling may
be a cause of ASD.
CTNNB1 (β-catenin) β-Catenin is a key intracellular
molecule in the canonical WNT signaling pathway and
Kumar et al. Journal of Neurodevelopmental Disorders           (2019) 11:10 Page 2 of 14
Ta
b
le
1
A
ut
is
m
sp
ec
tr
um
di
so
rd
er
(A
SD
)
ca
us
al
ge
ne
s
in
flu
en
ci
ng
W
N
T,
BM
P/
TG
F-
β,
SH
H
,F
G
F,
an
d
RA
si
gn
al
in
g
pa
th
w
ay
s
in
ve
rt
eb
ra
te
s
an
d
in
ve
rt
eb
ra
te
s
A
SD
ca
us
al
ge
ne
s
Re
gi
on
/n
eu
ro
ns
/c
el
ls
in
w
hi
ch
ge
ne
fu
nc
tio
n
is
af
fe
ct
ed
Sp
ec
ie
s
A
ffe
ct
ed
si
gn
al
in
g
pa
th
w
ay
Ph
en
ot
yp
es
/d
ow
ns
tr
ea
m
ta
rg
et
s
C
ita
tio
ns
5-
H
T
G
O
F
(g
ai
n-
of
-fu
nc
tio
n)
Bl
oo
d
H
um
an
TG
F-
β
TG
F-
β
pa
th
w
ay
id
en
tif
ie
d
as
a
no
ve
lh
yp
er
se
ro
to
ne
m
ia
-r
el
at
ed
A
SD
ge
ne
s
[1
8]
AL
D
H
1A
3
H
um
an
RA
[1
35
]
AN
K3
LO
F
(lo
ss
-o
f-f
un
ct
io
n)
P1
9
ce
lls
,p
ro
lif
er
at
in
g
ne
ur
al
pr
og
en
ito
rs
of
E1
6
m
ou
se
co
rt
ic
es
,E
15
br
ai
n
sl
ic
es
M
ou
se
W
N
T
(c
an
on
ic
al
)
In
cr
ea
se
s
pr
ol
ife
ra
tio
n
of
ne
ur
al
pr
og
en
ito
r
ce
lls
an
d
nu
cl
ea
r
β-
ca
te
ni
n
[8
5]
AP
C
LO
F
Fo
re
br
ai
n
ne
ur
on
s,
an
d
hi
pp
oc
am
pa
l,
co
rt
ic
al
,a
nd
st
ria
ta
lr
eg
io
ns
M
ou
se
W
N
T
(c
an
on
ic
al
)
Le
ar
ni
ng
an
d
m
em
or
y
im
pa
irm
en
ts
an
d
au
tis
tic
-li
ke
be
ha
vi
or
s
(in
cr
ea
se
d
re
pe
tit
iv
e
be
ha
vi
or
s,
re
du
ce
d
so
ci
al
in
te
re
st
)
[1
]
BT
BR
T+
Itp
r3
tf
/J
(B
TB
R)
m
ic
e
Sp
le
en
an
d
br
ai
n
tis
su
es
M
ou
se
TG
F-
β
D
ec
re
as
ed
TG
F-
β
le
ve
ls
[1
7]
CD
38
Ly
m
ph
ob
la
st
oi
d
ce
ll
lin
es
H
um
an
an
d
m
ou
se
RA
U
pr
eg
ul
at
io
n
of
C
D
38
by
RA
[1
40
,1
41
]
CH
D
8−
/−
LO
F
W
ho
le
M
ou
se
W
N
T
(c
an
on
ic
al
)
Em
br
yo
ni
ca
lly
le
th
al
[8
7]
CH
D
8+
/−
LO
F
N
uc
le
us
ac
cu
m
be
ns
(N
A
c)
M
ou
se
W
N
T
(c
an
on
ic
al
)
M
ac
ro
ce
ph
al
y,
cr
an
io
fa
ci
al
ab
no
rm
al
iti
es
,a
nd
be
ha
vi
or
al
de
fic
its
;
W
N
T
si
gn
al
in
g
up
re
gu
la
te
s
in
th
e
nu
cl
eu
s
ac
cu
m
be
ns
(N
A
c)
re
gi
on
of
th
e
br
ai
n
[8
9]
CT
N
N
B1
LO
F
Pa
rv
al
bu
m
in
in
te
rn
eu
ro
ns
M
ou
se
W
N
T
(c
an
on
ic
al
)
Im
pa
ire
d
ob
je
ct
re
co
gn
iti
on
an
d
so
ci
al
in
te
ra
ct
io
ns
;e
le
va
te
d
re
pe
tit
iv
e
be
ha
vi
or
s;
en
ha
nc
ed
sp
at
ia
lm
em
or
y
[6
6]
CT
N
N
B1
cK
O
LO
F
D
or
sa
ln
eu
ra
lf
ol
ds
M
ou
se
W
N
T
(c
an
on
ic
al
)
Sp
in
a
bi
fid
a
ap
er
ta
,c
au
da
la
xi
s
be
nd
in
g,
an
d
ta
il
tr
un
ca
tio
n
[6
5]
CT
N
N
B1
ha
pl
oi
ns
uf
fic
ie
nc
y
LO
F
W
ho
le
H
um
an
an
d
m
ou
se
W
N
T
(c
an
on
ic
al
)
N
eu
ro
na
ll
os
s,
cr
an
io
fa
ci
al
an
om
al
ie
s,
an
d
ha
ir
fo
lli
cl
e
de
fe
ct
s
[6
4]
D
H
CR
7
LO
F
M
EF
s
M
ou
se
SH
H
Im
pa
ire
d
SM
O
an
d
re
du
ce
d
SH
H
si
gn
al
in
g
[1
11
]
D
IX
D
C1
LO
F
M
ou
se
co
rt
ex
H
um
an
an
d
m
ou
se
W
N
T
(c
an
on
ic
al
)
Im
pa
ire
d
de
nd
rit
e
an
d
sp
in
e
gr
ow
th
,p
os
iti
ve
m
od
ul
at
or
of
W
N
T
si
gn
al
in
g
[7
9]
D
lx
5
G
O
F
2B
1
ce
ll
lin
e
M
ou
se
BM
P
U
pr
eg
ul
at
io
n
of
BM
P
bi
nd
in
g
en
do
th
el
ia
lr
eg
ul
at
or
(B
m
pe
r)
[1
3]
D
N
lg
4
LO
F
N
M
J
D
ro
so
ph
ila
BM
P
Re
du
ce
d
gr
ow
th
of
ne
ur
om
us
cu
la
r
ju
nc
tio
ns
(N
M
Js
)
w
ith
fe
w
er
sy
na
pt
ic
bo
ut
on
s
[1
0]
EN
2
G
O
F
Po
st
-m
or
te
m
sa
m
pl
es
H
um
an
SH
H
El
ev
at
ed
SH
H
ex
pr
es
si
on
[1
17
]
FG
F2
2/
FG
F7
LO
F
H
ip
po
ca
m
pa
lC
A
3
py
ra
m
id
al
ne
ur
on
s
M
ou
se
FG
F
Im
pa
ire
d
sy
na
ps
e
fo
rm
at
io
n
[1
24
]
FM
RP
de
pl
et
io
n
C
O
S-
7
ce
lls
M
on
ke
y
BM
P
In
cr
ea
se
in
BM
PR
2
an
d
ac
tiv
at
io
n
of
LI
M
K1
,s
tim
ul
at
es
re
or
ga
ni
za
tio
n
of
ac
tin
to
pr
om
ot
e
ne
ur
ite
ou
tg
ro
w
th
an
d
sy
na
ps
e
fo
rm
at
io
n
[1
1]
FO
XN
1
H
um
an
RA
[1
35
]
m
G
lu
R5
LO
F
C
or
tic
al
ne
ur
on
s
M
ou
se
FG
F
In
cr
ea
se
d
N
G
F
an
d
FG
F1
0
m
RN
A
le
ve
ls
[1
25
]
PG
E2
D
iff
er
en
tia
tin
g
ne
ur
on
al
ce
lls
H
um
an
s
W
N
T
(c
an
on
ic
al
)
U
pr
eg
ul
at
io
n
of
W
N
T3
an
d
TC
F4
[8
0,
93
,9
4]
PR
IC
KL
E2
LO
F
H
ip
po
ca
m
pa
ln
eu
ro
ns
M
ou
se
W
N
T
(n
on
-c
an
on
ic
al
)
A
lte
re
d
so
ci
al
in
te
ra
ct
io
n,
le
ar
ni
ng
ab
no
rm
al
iti
es
,a
nd
be
ha
vi
or
al
in
fle
xi
bi
lit
y
[4
0]
PT
CH
D
1
LO
F
D
en
ta
te
gy
ru
s
M
ou
se
SH
H
(h
yp
ot
he
tic
al
)
SH
H
in
de
pe
nd
en
t;
di
sr
up
te
d
sy
na
pt
ic
tr
an
sm
is
si
on
[1
09
]
RE
RE
H
um
an
RA
[1
37
]
Kumar et al. Journal of Neurodevelopmental Disorders           (2019) 11:10 Page 3 of 14
Ta
b
le
1
A
ut
is
m
sp
ec
tr
um
di
so
rd
er
(A
SD
)c
au
sa
lg
en
es
in
flu
en
ci
ng
W
N
T,
BM
P/
TG
F-
β,
SH
H
,F
G
F,
an
d
RA
si
gn
al
in
g
pa
th
w
ay
s
in
ve
rt
eb
ra
te
s
an
d
in
ve
rt
eb
ra
te
s
(C
on
tin
ue
d)
A
SD
ca
us
al
ge
ne
s
Re
gi
on
/n
eu
ro
ns
/c
el
ls
in
w
hi
ch
ge
ne
fu
nc
tio
n
is
af
fe
ct
ed
Sp
ec
ie
s
A
ffe
ct
ed
si
gn
al
in
g
pa
th
w
ay
Ph
en
ot
yp
es
/d
ow
ns
tr
ea
m
ta
rg
et
s
C
ita
tio
ns
RO
RA
LO
F
Ly
m
ph
ob
la
st
oi
d
ce
ll
lin
es
H
um
an
RA
Re
du
ce
d
pr
ot
ei
n
le
ve
ls
of
RO
RA
an
d
BC
L-
2
in
au
tis
tic
br
ai
n;
ab
er
ra
nt
m
et
hy
la
tio
n
[1
33
]
TC
F7
L2
LO
F
H
um
an
an
d
m
ou
se
W
N
T
(c
an
on
ic
al
)
Re
qu
ire
d
fo
r
th
al
am
oc
or
tic
al
ax
on
al
pr
oj
ec
tio
n
fo
rm
at
io
n
[6
8–
71
]
U
BE
3A
G
O
F
Pr
ef
ro
nt
al
co
rt
ex
M
ou
se
RA
N
eg
at
iv
e
re
gu
la
tio
n
of
A
LD
H
1A
2;
im
pa
ire
d
RA
-m
ed
ia
te
d
sy
na
pt
ic
pl
as
tic
ity
[1
39
]
ub
e3
a
LO
F
N
M
J
D
ro
so
ph
ila
BM
P
C
om
pr
om
is
ed
en
do
cy
to
si
s
in
th
e
N
M
Js
an
d
an
up
re
gu
la
te
d
BM
P
si
gn
al
in
g
in
th
e
ne
rv
ou
s
sy
st
em
[1
2]
U
BE
3A
T4
85
A
LO
F
H
EK
29
3T
ce
lls
H
um
an
W
N
T
(c
an
on
ic
al
)
St
ab
ili
ze
s
nu
cl
ea
r
β-
ca
te
ni
n
an
d
st
im
ul
at
es
ca
no
ni
ca
lW
N
T
si
gn
al
in
g
[7
8]
W
N
T1
,W
N
T2
,
W
N
T3
,W
N
T9
B
H
um
an
W
N
T
(c
an
on
ic
al
)
El
ev
at
ed
W
N
T3
ex
pr
es
si
on
in
th
e
pr
ef
ro
nt
al
co
rt
ex
of
A
SD
pa
tie
nt
s
[3
4,
41
–4
5]
Kumar et al. Journal of Neurodevelopmental Disorders           (2019) 11:10 Page 4 of 14
plays significant roles in development and disease [59, 60].
De novo CTNNB1 mutations have been reported in indi-
viduals with ASD, intellectual disability, microcephaly,
motor delay, and speech impairment [36, 39, 61–63].
CTNNB1 haploinsufficiency has been found to cause
neuronal loss, craniofacial anomalies, and hair follicle
defects in both humans and mice [64]. Conditional abla-
tion of β-catenin in the dorsal neural folds of mouse
embryos represses the expression of Pax3 and Cdx2 at the
dorsal posterior neuropore and leads to a decreased
expression of the WNT/β-catenin signaling target genes
T, Tbx6, and Fgf8 at the tail bud, resulting in spina bifida
aperta, caudal axis bending, and tail truncation [65]. Con-
ditional ablation of β-catenin in parvalbumin interneurons
in mice leads to impaired object recognition and social in-
teractions, as well as elevated repetitive behaviors, which
are core symptoms of ASD patients, and surprisingly, they
showed enhanced spatial memory [66]. These mice have
reduced c-Fos activity in the cortex, which is unaffected in
the dentate gyrus and the amygdala, suggesting a cell
type-specific role of β-catenin in the regulation of cogni-
tive and autistic-like behaviors [66].
TCF7L2 (TCF4) TCF7L2 is one of the TCF/LEF1 tran-
scription factors in the canonical WNT/β-catenin signal-
ing pathway and is associated with type II diabetes in
humans [67]. De novo loss-of-function variants of TCF7L2
have been found in ASD patients [68, 69]. In mice, Tcf7l2
is required for the formation of thalamocortical axonal
projections, as is the key Wnt co-receptor Lrp6 [70, 71],
suggesting that abnormal thalamocortical axonal inputs
may contribute to ASD. It remains unclear if other mem-
bers of the TCF/Lef1 transcription factors are associated
with ASD.
Core components of non-canonical WNT signaling
PRICKLE2 PRICKLE2 variants (p.E8Q and p.V153I) have
been reported in ASD patients [40]. PRICKLE2’s role in
ASD is further supported by the finding of a 3p interstitial
deletion including PRICKLE2 in identical twins with ASD
[72]. Prickle2-deficient mice display ASD-like phenotypes,
such as altered social interaction, learning abnormalities,
and behavioral inflexibility [40]. PRICKLE2 is known to
interact with post-synaptic density protein-95 (PSD-95),
and this relationship is enhanced by Vangl2, a key compo-
nent in the non-canonical WNT/PCP (planar cell polarity)
pathway [73]. Reduced dendrite branching, synapse num-
ber, and PSD size have been observed in hippocampal
neurons of Prickle2-deficient mice [40]. An in vitro study
shows that Prickle1 and Prickle2 promote neurite out-
growth via a Dvl-dependent mechanism [74]. Future
works need to address the involvement of other PCP
genes and the signaling interaction between the PCP and
WNT/β-catenin signaling pathways in ASD etiology.
Fig. 1 Possible interactions between ASD causal genes and WNT signaling. Most molecules (red) encoded by the ASD-associated genes are
either core components of WNT signaling pathways, such as WNTs, APC, β-catenin, TCF7L2, and PRICKLE2, or their modulators, such as DIXDC1,
PGE2, UBE3A, and CHD8. ANK3 interacts with β-catenin at the plasma membrane. Note: plus sign indicates upregulation; minus sign
indicates downregulation
Kumar et al. Journal of Neurodevelopmental Disorders           (2019) 11:10 Page 5 of 14
Modulators and effectors of WNT signaling in ASD etiology
Several ASD-associated genes are direct or indirect
modulators of WNT signaling, such as ankyrin-G
(ANK3) [75–77], chromodomain helicase DNA-binding
protein 8 (CHD8) [5, 6], HECT domain E3 ubiquitin lig-
ase (UBE3A) [78], DIX domain-containing 1 (DIXDC1)
[79], and Prostaglandin E2 (PGE2) [80] (Table 1 and
Fig. 1). Intriguingly, a recent study suggests that the
ASD-associated gene Neuroligin 3 (Nlgn3) is a direct
downstream target of WNT/β-catenin signaling during
synaptogenesis [81] (Fig. 1).
ANK3 Whole-genome and whole-exome sequencing
studies in ASD patients have identified mutations in
ANK3 gene [75–77]. Ankyrin-G, a scaffolding protein
encoded by ANK3 gene, localizes to the axon initial seg-
ment (AIS) and the nodes of Ranvier, where it has roles
in the assembly and maintenance of the AIS and neur-
onal polarity [82, 83]. Ankyrin-G facilitates cell-cell con-
tact by binding to E-cadherin at a conserved site distinct
from that of β-catenin and localizes it to the cell adhe-
sion site along with β-2-spectrin in early embryos and
cultured epithelial cells [84]. Ankyrin-G is enriched at
the ventricular zone of the embryonic brain, where it
regulates the proliferation of neural progenitor cells [85].
Ankyrin-G LOF increases the proliferation of neural
progenitor cells and nuclear β-catenin, probably by dis-
ruption of the β-catenin/cadherin interaction [85].
CHD8 CHD8, an ATP-dependent chromatin remodeler,
interacts with β-catenin and negatively regulates the ex-
pression of β-catenin-targeted genes [86]. CHD8 binding
to p53 leads to the formation of a trimeric complex with
histone H1 on chromatin, which suppresses p53-dependent
transactivation and apoptosis during early embryogenesis
[87]. CHD8 is also required for the expression of E2 adeno-
virus promoter-binding factor target genes during the G1/S
transition of the cell cycle [88]. Chd8 gene knockout
(Chd8−/−) in mice is embryonic lethal [87], whereas its het-
erozygous LOF mutations (Chd8+/−) result in mice with
macrocephaly, craniofacial abnormalities, and behavioral
deficits [89]. Its knockdown in SK-N-SH human neural
progenitor cells alters the expression of genes involved in
neuronal development [90]. WNT signaling is upregulated
in the nucleus accumbens (NAc) region of the brain of
Chd8+/− mice, highlighting the critical role CHD8 plays in
the regulation of WNT signaling in the NAc [89].
UBE3A Dysfunction of UBE3A is linked to autism,
Angelman syndrome, and cancer [78]. UBE3AT485A, a de
novo autism-linked UBE3A mutant that disrupts phos-
phorylative control of UBE3A activity, ubiquitinates mul-
tiple proteasome subunits, reduces proteasome subunit
abundance and activity, stabilizes nuclear β-catenin, and
stimulates canonical WNT signaling more effectively than
the wild-type UBE3A [78].
DIXDC1 Rare missense variants in DIXDC1 were iden-
tified in ASD patients [79]. These variants prevent phos-
phorylation of DIXDC1 isoform 1, causing impairment
to dendrite and spine growth [79]. DIXDC1 is a positive
modulator for WNT signaling and regulates excitatory
neuron dendrite development and synapse function in the
mouse cortex [79]. MARK1, which is also linked to ASD,
phosphorylates DIXDC1 to regulate dendrite and spine
development through modulation of the cytoskeletal net-
work in an isoform-specific manner [79]. Dixdc1-deficient
mice exhibit behavioral disorders, including reduced social
interaction, which can be alleviated through pharmaco-
logical inhibition of Gsk3 to upregulate WNT/β-catenin
signaling [91, 92]. These studies suggest a potential ap-
proach to ASD treatment through manipulation of WNT/
β-catenin signaling activities.
PGE2 PGE2, an endogenous lipid molecule, has been
linked to ASD and alters the expression of downstream
WNT-regulated genes previously associated with neuro-
developmental disorders [80]. The link between prosta-
glandin and autism came from the report of Möbius
sequence with autism and positive history of misopros-
tol use during pregnancy [93]. The prostaglandin ana-
log misoprostol is used as an abortifacient as well as
for the prevention of gastric ulcers. Among seven chil-
dren with ASD, four (57.1%) had prenatal exposure to
misoprostol [93, 94]. In undifferentiated stem cells,
PGE2 downregulates PTGS2 expression and upregu-
lates MMP9 and CCND1 expression, whereas in differ-
entiating neuronal cells, PGE2 causes upregulation of
WNT3, TCF4, and CCND1 [80].
NLGN3 Mutations in neuroligins NLGN3 and NLGN4
have been reported in autistic patients [95]. These type I
transmembrane proteins are neural cell adhesion mole-
cules and are required for the formation and develop-
ment of synapses [10]. Chromatin immunoprecipitation
and promoter luciferase assays demonstrate that WNT/
β-catenin signaling directly regulates Nlgn3 expression
[81]. It will be important to address whether WNT/β-ca-
tenin signaling regulates other ASD-associated genes.
Altered TGF-β/BMP signaling in ASD
The TGF-β/activin and the bone morphogenetic protein
(BMP)/growth and differentiation factor (GDF) are the
two subgroups of TGF-β superfamily [96]. BMPs consti-
tute the largest subdivision of the TGF-β superfamily
[97] and are critical in the development of the nervous
system [98]. Their signaling has been shown to be dys-
regulated in ASD. BMPs regulate the expression of
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various genes by the canonical pathway (Smad-depen-
dent) and non-canonical pathways (such as MAPK cas-
cade) [99]. In the canonical pathway, the binding of
BMPs to type I or type II serine/threonine kinase recep-
tors forms a heterotetrameric complex. This leads to the
transphosphorylation of the type I receptor by the type
II receptor. The type I receptor then phosphorylates the
R-Smads (Smad1/5/8). The phosphorylated Smad1/5/8
along with the co-Smad (Smad4) translocate to the
nucleus and regulate gene expression. There are various
factors such as plasma membrane co-receptors and
extracellular and intracellular factors known to modulate
BMP signaling [99]. BTBR T+Itpr3tf/J (BTBR) mice are
widely used in the study of ASD [17]. It has been
reported that TGF-β levels are reduced in BTBR mice in
comparison with B6 mice [17] (Table 1). Significant
changes in the expression of TGF-β have been found in
the spleen and brain tissues of BTBR mice compared to
those in adenosine A2A receptor (A2AR) agonist CGS
21680 (CGS)-treated mice [17]. ASD has been linked
with higher levels of serotonin (5-hydroxytryptamine or
5-HT) in the blood [18] (Table 1). In a network-based
gene set enrichment analysis (NGSEA), components of
the TGF-β pathway have been identified as novel
hyperserotonemia-related ASD genes, based on LOF and
missense de novo variants (DNVs) [18].
NLGN4 Drosophila neuroligin 4 (DNlg4) LOF results in
reduced growth of neuromuscular junctions (NMJs),
with fewer synaptic boutons due to the reduction in the
bone morphogenetic protein (BMP) type I receptor
thickvein (Tkv) [10], suggesting important roles of BMP
signaling in normal and autistic brains.
FMR1 Fragile X syndrome (FXS) is the most common her-
itable form of intellectual disability and ASD, which is
caused due to the silencing of FMR1 [11]. FMR1 protein
(FMRP) depletion results in an increase in the bone mor-
phogenetic protein type II receptor (BMPR2) and activation
of a non-canonical BMP signaling component LIM domain
kinase 1 (LIMK1), which stimulates reorganization of actin
to promote neurite outgrowth and synapse formation [11].
Increased BMPR2 and LIMK1 activity has been reported in
the prefrontal cortex of FXS patients compared with that of
healthy subjects [11].
UBE3A The inhibition of BMP signaling by Ube3a has
been reported to play a role in the regulation of synapse
growth and endocytosis [12]. A direct substrate of ube3a,
the BMP receptor Tkv, is degraded through the
ubiquitin-proteasome pathway [12]. Drosophila ube3a has
been known to regulate the NMJ development in the pre-
synaptic neurons through the BMP signaling pathway
[12]. Drosophila ube3a mutants have been shown viable
and fertile. However, they display compromised endocyto-
sis in the NMJs and upregulated BMP signaling in the ner-
vous system due to an increase in Tkv [12].
DLX The DLX genes encoding homeodomain transcrip-
tion factors have been associated with ASD [100–102].
These genes control craniofacial patterning and differen-
tiation and survival of forebrain inhibitory neurons
[100]. The BMP-binding endothelial regulator (Bmper)
has been found upregulated in a cell line overexpressing
Dlx5 [13], suggesting dysregulated DLX function in ASD
patients may lead to altered BMP signaling.
Altered SHH signaling in ASD
SHH plays a crucial role in the organization of the verte-
brate brain [103]. SHH has a wide range of roles in devel-
oping as well as the adult brain and drives proliferation,
specification, and axonal targeting within the forebrain,
hindbrain, and spinal cord [104]. Although the role of
neural primary cilia in embryonic CNS patterning is well
studied, their role in adult CNS plasticity has recently
emerged [105]. SHH signaling at the primary cilium has
been described [106] and is summarized in Fig. 2. In the
absence of SHH activity, PTCH represses SMO. This leads
to the phosphorylation of GLI proteins, and their subse-
quent proteolytic truncation into repressor forms that in-
hibit transcriptional activity. However, the binding of SHH
to PTCH causes its internalization followed by degrad-
ation which in turn leads to SMO accumulation and phos-
phorylation. In this case, GLI is transported to the cytosol
and enters the nucleus in its full form, which further acti-
vates target transcription. Pathological roles of SHH, In-
dian hedgehog (IHH), and BDNF have been suggested in
Fig. 2 Possible interactions between ASD causal genes and SHH
signaling. The genes encoded for PTCHD1, EN2, and DHCR7 are
potential ASD genes. Note: minus sign indicates downregulation;
question mark indicates undefined role of PTCHD1 in SHH signaling
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children with ASD [14]. SHH signaling influences neuro-
genesis and neural patterning during the development of
the central nervous system. Dysregulation of SHH signal-
ing in the brain leads to neurological disorders like ASD
[15]. SHH has also been associated with oxidative stress in
autism [107]. Significantly higher levels of oxygen free rad-
icals (OFR) and serum SHH protein have been demon-
strated in autistic children, suggesting a pathological role
of oxidative stress and SHH in ASD [108]. Figure 2
summarizes the interaction between ASD causal genes
and SHH signaling.
PTCHD1 Mutations in the gene patched
domain-containing 1 (PTCHD1) have been reported in
ASD and ID patients [109]. Ptchd1 KO male mice exhibit
cognitive alterations [109]. LOF experiments do not sup-
port a role for PTCHD1 protein in SHH-dependent sig-
naling but reveal a disruption of synaptic transmission in
the mouse dentate gyrus [109]. PTCHD1 has been shown
to bind with the post-synaptic proteins PSD95 and
SAP102 [110]. Ptchd1 deficiency in male mice (Ptchd1−/y)
induces global changes in synaptic gene expression, affects
the expression of the immediate-early expression genes
Egr1 and Npas4, and impairs excitatory synaptic structure
and neuronal excitatory activity in the hippocampus, lead-
ing to cognitive dysfunction, motor disabilities, and hyper-
activity [110].
DHCR7 The impaired function of the cholesterol
biosynthetic enzyme 7-dehydrocholesterol reductase
(DHCR7) has been associated with the ASD [111]. The ac-
tivation of the transmembrane protein Smoothened
(SMO), through which SHH signaling is transduced, and
its localization to the primary cilium is affected by condi-
tions of reduced cholesterol biosynthesis [111].
EN2 The transcription factor engrailed2 (EN2) has been
associated with ASD [112–116]. The increased levels of
EN2 in affected individuals with EN2 ASD-associated
haplotype (rs1861972-rs1861973 A-C) further support
the susceptibility of EN2 gene for ASD [77, 117, 118].
The increased EN2 levels result in the elevated levels of
the SHH expression as reported in post-mortem samples
[117]. SHH is one of the genes flanking EN2 which is
coexpressed during brain development [119, 120].
Altered FGF signaling in ASD
FGF signaling plays a crucial role in brain patterning,
and its malfunction can result in various neurological
disorders [121]. There are 18 secreted FGFs and 4 tyro-
sine kinase FGF receptors (FGFRs) reported in the mam-
malian FGF family whose interaction is regulated by
cofactors and extracellular binding proteins [122].
Activation of FGFRs leads to the phosphorylation of tyro-
sine residues which further results in the interaction
between cytosolic adaptor proteins and the RAS-MAPK,
PI3K-AKT, PLCγ, and STAT intracellular signaling path-
ways [122]. Dysregulation of FGF signaling has been
suggested to play a role in the pathogenesis of ASD [16].
For instance, cortical abnormalities observed in autistic
brains have been associated with defective FGF signaling
[121, 123]. Perturbations in the number of excitatory and
inhibitory synapses have been implicated in ASD [124].
Mutant mice lacking FGF22 or FGF7, which displayed im-
paired synapse formation in the hippocampal CA3 pyram-
idal neurons, have been reported [124], supporting the
pathological role of dysregulated FGF signaling in ASD
(Table 1). The metabotropic glutamate receptor 5
(mGluR5) LOF results in aberrant dendritogenesis, one of
the characteristics observed in autistic brains, in the
cortical neurons by increasing nerve growth factor (NGF)
and FGF10 mRNA levels [125] (Table 1).
Altered retinoic acid signaling in ASD
Retinoic acid (RA), the functional metabolite of vitamin
A, is an essential morphogen in vertebrate development
[126, 127]. RA mediates both genomic transcriptional
effects by binding to nuclear receptors called retinoic
acid receptors (RARs) and retinoid X receptors (RXRs)
as well as non-genomic effects such as retinoylation (RA
acylation), a post-translational modification of proteins
[128, 129]. A range of co-activators and co-repressors
have been reported in modulating RA signaling activity
[129]. In the developing CNS, RA is required for neural
patterning, differentiation, proliferation, and the estab-
lishment of neurotransmitter systems [130]. RA from
the meninges regulates cortical neuron generation [131].
Vitamin A deficiency may induce ASD-like behaviors in
rats [132]. It has been proposed that an abnormality in
the interplay between retinoic acid and sex hormones
may cause ASD [19]. Aberrant methylation and de-
creased protein expression of retinoic acid-related
orphan receptor alpha (RORA) have been found in the
autistic brain [133], while RORA variants have been as-
sociated with ASD [134]. Whole-exome sequencing in a
South American cohort links RA signaling genes, includ-
ing an RA-synthesizing gene aldehyde dehydrogenase 1
family member A3 (ALDH1A3) and the RORA-regulated
FOXN1 to ASD [135]. Low level of ALDH1A1 has been
found in a subset of autistic patients [136]. De novo mu-
tations in arginine-glutamic acid dipeptide repeats
(RERE) that encode a nuclear receptor coregulator for
RA signaling may cause ASD and other defects associ-
ated with proximal 1p36 deletions [137]. Genome-wide
chromatin immunoprecipitation analysis revealed that
RORA transcriptionally regulates several ASD-relevant
genes, including NLGN1 [138]. Intriguingly,
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overexpression of UBE3A represses ALDH1A2 and im-
pairs RA-mediated synaptic plasticity in ASD, which can
be alleviated by RA supplements [139]. All-trans-RA can
upregulate the reduced CD38 expression in lymphoblas-
toid cell lines from ASD, while CD38-deficient mice ex-
hibit ASD-like behavior [140, 141]. Beta-carotene, a
precursor of vitamin A, has been shown as a potential
treatment of autistic-like behavior in BTBR mice [142].
A synthetic RORA/G agonist has been tested to alleviate
autistic disorders in a mouse model [143]. These studies
suggest therapeutic approaches for treating ASD by
targeting RA and related signaling pathways. The
possible interactions among ASD causal genes and RA
signaling have been described in Fig. 3.
Non-genetic etiologies of ASD and altered
signaling pathways
Various exogenous factors, such as prenatal exposure to
viral infection or VPA, lead to several neurodevelopmental
disorders with perturbed WNT signaling (Fig. 1). The
transcription factor GATA-3 is critical for the brain
development [144] and is involved in the WNT [145] and
TGF-β/BMP [146, 147] signaling pathways. An increase in
binding to GATA sites in DNA has been reported while
exposure to thalidomide, valproate, and alcohol is known
to cause ASD [148].
Viral infection The infection with rubella in early preg-
nancy has been linked to autism in clinical and
epidemiological studies [149]. Prenatal viral-like immune
activation has recently been reported to induce stable
hyper- and hypomethylated CpGs at WNT signaling
genomic regions (WNT3, WNT7B, WNT8A) which fur-
ther disrupt the transcription of downstream target
genes [150], suggesting a potential role of epigenetic
modulation of WNT signaling in ASD etiologies.
VPA The use of the anticonvulsant valproic acid (VPA)
during early pregnancy has been reported to cause aut-
ism in 11% children and autistic traits in an even larger
number of children [151]. VPA is used in the treatment
of epilepsy and bipolar disorder. However, rat prenatal
exposure to VPA results in animals that are susceptible
to autism-like phenotypes [20]. Prenatally VPA-treated
rats exhibit an imbalance in oxidative homeostasis that
facilitates susceptibility to autism [20, 152]. VPA treat-
ment in rats resulted in lowered social interaction, lon-
ger moving time in the central area, and reduced
standing times. Sulindac is a small molecule inhibitor
of the WNT/β-catenin signaling pathway [20, 152].
Sulindac treatment can correct the VPA-induced
autistic-like behaviors, p-Gsk3β downregulation, and
β-catenin upregulation in the prefrontal lobe, hippo-
campus, and cerebellum [152].
Conclusions
ASD causal genes may act upstream or downstream of
WNT, BMP/TGFβ, SHH, FGF, and RA signaling
Fig. 3 Possible interactions between ASD causal genes and RA signaling. UBE3A affects ALDH1A expression and thereby affects retinoic acid
signaling pathway. RORA is associated with ASD which influences NLGN1. The RA signaling coregulator RERE is also associated with ASD
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pathways in vertebrates and invertebrates (Table 1 and
Figs. 1, 2, 3, and 4). Alteration in these signaling path-
ways during brain development seems to cause ASD and
other neurodevelopmental disorders. Previous studies
support possible roles for these signaling pathways in
the design of therapeutic targets for autism. However,
systematic developmental studies are required to identify
the temporal window in which impairment of these sig-
nals has the most significant impact on brain structure
and function and resulting behavioral impairment. Such
studies may also help in elucidating the upstream and
downstream signaling pathways in the etiology of neuro-
developmental disorders as well as the mechanisms be-
hind a particular impaired behavior. Although crosstalk
among signaling pathways has been reported in several
developmental processes and related diseases, similar
studies in autistic models are lacking. Crosstalk between
WNT and Hedgehog/Gli signaling in colon cancer has
been studied and suggested as a potential target for its
treatment [153]. β-Catenin and Gli1 are negatively regu-
lated by GSK3β and CK1α [154–156] and have antagonis-
tic roles in regulating TCF and downstream target genes
in metastatic colon cancer [157]. The suppressor of the
fused kinase (Sufu), a negative regulator of Gli1, has been
reported to regulate the distribution of β-catenin in the
nucleus and cytoplasm [158–160]. In colon cancer, loss of
either PTEN or p53 leads to the activation of both
β-catenin and Gli1 [157, 161]. The inhibition of SMO, an
upstream active factor of Gli1, has been shown to reduce
active β-catenin levels and induce its nuclear exclusion
[162]. Gli1 negatively regulates Gli3R and vice versa [157].
Further, Gli3R has been shown to inhibit the activity of
β-catenin [163]. The transcription of Wnt2b, Wnt4, and
Wnt7b is shown to be induced by Gli1 [164]. The cross-
talk between TGF-β and SHH pathways has also been re-
ported in cancer [165], as well as in
cyclosporine-enhanced cell proliferation in human gin-
gival fibroblasts [166]. Neuropilin-1 (NRP1), a TGF-β
co-receptor expressed on the membrane of cancer cells, is
known to enhance the canonical SMAD2/3 signaling in
response to TGF-β [167]. Further, HH signaling increases
NRP1 transcription and NRP1 is also reported to increase
the activation of HH target genes by mediating HH trans-
duction between activated SMO and SUFU [168, 169].
While TGF-β is important for SMO-mediated cancer de-
velopment [170], its role in the induction of GLI2 and
GLI1 expression by inhibition of PKA activity has also
been reported [171]. A hierarchical pattern of crosstalk
has been suggested in which TGF-β upregulates Shh and
leads to cyclosporine-enhanced Shh expression and cell
proliferation in gingival fibroblasts [166]. Crosstalk be-
tween FGF and WNT pathways has been observed in zeb-
rafish tailbud [172] and mouse craniofacial development
[173]. Reciprocal positive regulation between FGF and
WNT signaling has been observed [172]. WNT/β-catenin
signaling in the anterior neural ridge and facial ectoderm
has been shown to positively target Fgf8, and β-catenin
GOF leads to ectopic expression of Fgf8 in the facial ecto-
derm [173]. Wnt has been reported to increase FGF sig-
naling within the Mapk branch by elevating Erk
phosphorylation levels [172]. Further, Fgf has been shown
to inhibit the Wnt antagonists, dkk1 and notum1a, result-
ing in the elevation of WNT signaling [172]. A LOF muta-
tion in UBE3A, an ASD-associated gene, influences both
the WNT and BMP signaling pathways, suggesting pos-
sible crosstalk between them [12, 78]. Xu et al. further
demonstrated that excessive UBE3A impairs RA-mediated
neuronal synaptic plasticity in ASD probably by negative
regulation of ALDH1A2, the rate-limiting enzyme of ret-
inoic acid (RA) synthesis. [139]. Medina et al. [81] sug-
gested that while Nlgn3 is a direct target of WNT/
β-catenin signaling, the ASD-associated gene may also
regulate BMP signaling. These results suggest that signal-
ing crosstalk among morphogenetic pathways is mediated
by autistic causal genes, thereby demonstrating value in
further in-depth studies on interactions between signaling
molecules in normal physiological and diseased condi-
tions. Evidence has suggested a tissue-specific mechanism
behind WNT and BMP signaling crosstalk [174]. More-
over, WNT signaling may repress RA signaling during
orofacial development [175], while WNT signaling posi-
tively regulates RA signaling in the dorsal optic cup during
eye development [176], suggesting context-dependent
mechanisms of signaling interactions. Therefore, the inter-
action between various signaling pathways should be stud-
ied in neuronal as well as glial cells for ASD, which may
help in designing treatment and targeting perturbed sig-
naling in a cell-specific manner. Among the nine
high-confidence ASD risk genes, only a few have been
studied so far in the context of impaired signaling path-
ways. The investigation of roles for other ASD genes in
neurodevelopment and in the regulation of various signal-
ing pathways may increase the understanding of mecha-
nisms behind the etiology of ASD. Overall, this article
Fig. 4 ASD causal genes affecting BMP signaling and potential
crosstalk with other signaling pathways. ASD causal genes-encoded
proteins, such as NLGN3/4, FMR1, DLX, and UBE3A, interact with
BMP signaling pathway which may further affect WNT signaling. It
should be noted that overexpression of UBE3A affects WNT and RA
signaling pathways. However, its loss-of-function affects BMP
signaling. Note: plus sign indicates upregulation; minus sign
indicates downregulation
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proposes to study how different ASD causal genes interact
with each signaling pathway in the development of the
brain and whether there is any crosstalk between them.
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